DAPA-HF is the first heart failure outcomes trial ... and randomly assigned them to once daily dapagliflozin 10 mg or 5 mg or matching placebo. People with type 1 diabetes mellitus or those ...

PHILADELPHIA — New analyses of the DAPA-HF trial suggest that the benefits ... treatment with dapagliflozin (Farxiga, AstraZeneca) 10 mg once daily in patients with HF with reduced ejection ...

In DAPA-CKD, “What was quite surprising is that ... Patients were randomized 1:1 to dapagliflozin 10 mg or placebo once daily alongside standard of care (ACE inhibitor or ARB).

In CAMEO-DAPA, he and his colleagues hypothesized that 24 weeks of ... with 38 ultimately receiving treatment with either placebo or dapagliflozin 10 mg once daily. At baseline, mean PCWP measured ...

The DAPA-MI trial sought to reduce the risk of recurrent MI ... They were randomized to either 10 mg of dapagliflozin on top of standard care, or to placebo. Follow-up occurred within the first 6-10 ...